Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Research & Drug Development
2001
Zecca L.; Tampellini D.; Gerlach M.; Riederer P.; Fariello R.G.; Sulzer D.
Substantia Nigra Neuromelanin: Structure, Synthesis and Molecular Behaviour.
Mol. Pathol., 54(6): 414-8, 2001
Veneroni O.; Maj R.; Calabresi M.; Fariello R.G.; Benatti L.; Salvati P.
NW-1029, a Novel Na+Channel Blocker Is Effective in Animal Models of Chronic Pain.
Italian Pharmacology Society, Pharmacological Research, 43, SUP A26 2001